More children with the rare genetic disorder spinal muscular atrophy (SMA) can now be treated with Spinraza after NICE today (3 July) published amended draft guidance following a proposal for extending the terms of the managed access agreement (MAA) between NHS England and Biogen for funding it.
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (0)
- In development advice (0)
Guidance by programme
Review the evidence across broad health and social care topics.
Reviews the clinical and cost-effectiveness of new treatments.
Review new diagnostic technologies for adoption in the NHS.
Review clinical and cost-effectiveness of specialised treatments.
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Reviews new medical devices for adoption in the NHS.
Advice by programme
Review the evidence and likely costs of medical devices and technologies.
Products being developed or updated
News on this topic
Putting guidance into practice
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 3 of 7 shared learning examples for this topic: